Nurix therapeutics reports fiscal first quarter 2022 financial results and provides a corporate update

Dosed first patient in the phase 1 trial of detil-0255, nurix's drug-enhanced tumor infiltrating lymphocyte (til) program
NRIX Ratings Summary
NRIX Quant Ranking